Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Louis

Showing results (531-540 of 576) with videos related to

Pageof 58
Sort By:
The Journal of Infectious Diseases|June 2, 2011
Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19Robin McKenzie, Chad K Porter, Joyce A Cantrell, et al.
Plos Neglected Tropical Diseases|October 3, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelXueyan Zhang, Jessica Brubaker, Kawsar R Talaat, et al.
Journal of Medical Internet Research|July 22, 2014
Longitudinal accuracy of web-based self-reported weights: results from the Hopkins POWER TrialGerald J Jerome, Arlene Dalcin, Janelle W Coughlin, et al.
AIDS (London, England)|March 28, 1998
A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDSC L Brosgart, T A Louis, D W Hillman, et al.
Infection and Immunity|January 24, 2006
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adultsRobin McKenzie, A Louis Bourgeois, Fayette Engstrom, et al.
Infection and Immunity|January 21, 2010
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humansDavid R Tribble, Shahida Baqar, Daniel A Scott, et al.
Microorganisms|October 28, 2023
Efficacy of an Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity ScoreNicole Maier, Shannon L Grahek, Jane Halpern, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Journal of Clinical Microbiology|March 8, 2005
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrheaAmy R Chapin, Colleen M Carpenter, William C Dudley, et al.
Journal of Comparative Effectiveness Research|November 19, 2013
From efficacy to effectiveness: lessons learned from the Practice-Based Opportunities for Weight Reduction (POWER) trialGerald J Jerome, Richard R Rubin, Jeanne M Clark, et al.
Pageof 58

Showing results (531-540 of 576) with videos related to

Sort By:
Pageof 58
The Journal of Infectious Diseases|June 2, 2011
Volunteer challenge with enterotoxigenic Escherichia coli that express intestinal colonization factor fimbriae CS17 and CS19Robin McKenzie, Chad K Porter, Joyce A Cantrell, et al.
Plos Neglected Tropical Diseases|October 3, 2025
Intestinal inflammation induced by heat-labile toxin-producing enterotoxigenic E: Coli infection and impact on immune responses in an experimental human challenge modelXueyan Zhang, Jessica Brubaker, Kawsar R Talaat, et al.
Journal of Medical Internet Research|July 22, 2014
Longitudinal accuracy of web-based self-reported weights: results from the Hopkins POWER TrialGerald J Jerome, Arlene Dalcin, Janelle W Coughlin, et al.
AIDS (London, England)|March 28, 1998
A randomized, placebo-controlled trial of the safety and efficacy of oral ganciclovir for prophylaxis of cytomegalovirus disease in HIV-infected individuals. Terry Beirn Community Programs for Clinical Research on AIDSC L Brosgart, T A Louis, D W Hillman, et al.
Infection and Immunity|January 24, 2006
Comparative safety and immunogenicity of two attenuated enterotoxigenic Escherichia coli vaccine strains in healthy adultsRobin McKenzie, A Louis Bourgeois, Fayette Engstrom, et al.
Infection and Immunity|January 21, 2010
Assessment of the duration of protection in Campylobacter jejuni experimental infection in humansDavid R Tribble, Shahida Baqar, Daniel A Scott, et al.
Microorganisms|October 28, 2023
Efficacy of an Enterotoxigenic <i>Escherichia coli</i> (ETEC) Vaccine on the Incidence and Severity of Traveler's Diarrhea (TD): Evaluation of Alternative Endpoints and a TD Severity ScoreNicole Maier, Shannon L Grahek, Jane Halpern, et al.
Plos One|March 4, 2016
An Evidenced-Based Scale of Disease Severity following Human Challenge with Enteroxigenic Escherichia coliChad K Porter, Mark S Riddle, Ashley N Alcala, et al.
Journal of Clinical Microbiology|March 8, 2005
Prevalence of norovirus among visitors from the United States to Mexico and Guatemala who experience traveler's diarrheaAmy R Chapin, Colleen M Carpenter, William C Dudley, et al.
Journal of Comparative Effectiveness Research|November 19, 2013
From efficacy to effectiveness: lessons learned from the Practice-Based Opportunities for Weight Reduction (POWER) trialGerald J Jerome, Richard R Rubin, Jeanne M Clark, et al.
Pageof 58